Mode
Text Size
Log in / Sign up
N/A Completed N=25 Treatment

Natural Killer (NK) Cell Transplantation for AML

Source: ClinicalTrials.gov NCT00187096 ↗
Enrolled (actual)
25
Serious AEs
12.0%
Results posted
Nov 2012
Primary outcomePrimary: Number of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant — 2; 3; 11 participants

Summary

The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant
2; 3; 11 —
PRIMARY
Proportion of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant
0.20; 1.00; 0.917 —
SECONDARY
Duration of Engraftment of Natural Killer (NK) Cells
10 —
SECONDARY
Percent of Peak NK Cell Chimerism
7 —
SECONDARY
Percent of Detectable Donor NK Cells at Day 28
29 —
SECONDARY
Day That Maximum NK Cell Engraftment Was Reached
14 —
SECONDARY
Number of KIR-mismatched NK Cells
210; 5,800 —
SECONDARY
Number of Participants With Evidence of NK Cells Lysing a Target Cell Line (K562)
10; 0 —
SECONDARY
Relapse-free Survival
100 —
SECONDARY
Overall Survival
100; 0; 45.0 —

Eligibility Criteria

Inclusion Criteria

  • Participants with AML that is in complete remission, is relapsed or refractory, or with increasing minimal residual disease.
  • Participants in complete remission must have recovered from toxicity of previous therapy and have evidence of bone marrow recovery
  • Participants who had prior stem cell transplant (SCT) must have no evidence of GVHD and 60 or more days have elapsed since the SCT.

Exclusion Criteria

  • Participants who are pregnant
  • Participants with inadequate renal, liver, or pulmonary functions
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00187096). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search